$ORKA News

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Oruka Therapeutics - Intriguing Long Acting Psoriasis Programs May Need Further Derisking

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares

UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate

Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)

Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough

Halozyme and Oruka sign agreement for Hypercon technology

Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis - Slideshow